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Quality of Care for Atrial Fibrillation
Among Patients Hospitalized for Heart Failure
Jonathan P. Piccini, MD,* Adrian F. Hernandez, MD, MHS,* Xin Zhao, PHD,*
Manesh R. Patel, MD,* William R. Lewis, MD,† Eric D. Peterson, MD, MPH,*
Gregg C. Fonarow, MD,‡ for the Get With The Guidelines Steering Committee and Hospitals
Durham, North Carolina; Cleveland, Ohio; and Los Angeles, California
Objectives This study sought to examine quality of care and warfarin use at discharge in patients with atrial fibrillation (AF)
and heart failure (HF).
Background Atrial fibrillation is common in HF, and national guidelines recommend discharge on warfarin for stroke prophy-
laxis. However, the frequency and factors associated with the guideline adherence are poorly described.
Methods We analyzed 72,534 HF admissions from January 2005 through March 2008 at 255 hospitals participating in
the American Heart Association’s Get With The Guidelines HF program. Multivariable logistic regression was
used to identify independent factors associated with warfarin use at discharge.
Results In this HF population, 20.5% (n  14,901) had AF on admission, whereas another 13.7% (n  9,918) had a
prior history of AF but were in a regular rhythm at admission. Contraindications to warfarin therapy were docu-
mented in 9.2%. Among eligible HF patients without contraindications, the median prevalence of warfarin ther-
apy at discharge was 64.9% (interquartile range 55.5 to 73.4) and did not improve during the 3.5 years of study.
After adjustment, major factors associated with no warfarin use at discharge included increasing age, nonwhite
race, anemia, and treatment in the south. Warfarin use also varied inversely with CHADS2 (congestive heart fail-
ure, hypertension, age 75, diabetes, and prior stroke or transient ischemic attack) risk (70.9% to 59.5% for
CHADS2 score 1 to 6, p  0.0001).
Conclusions Guideline-recommended warfarin use in patients with AF and HF is less than optimal, has not improved over
time, and varies significantly according to age, race, risk profile, region, and hospital site. (J Am Coll Cardiol
2009;54:1280–9) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.091s
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nent and converging epidemics in the U.S. health care
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009, accepted April 3, 2009.ystem (1,2). After a hospitalization for HF, 1-year mortal-
ty exceeds 30% and readmission rates approach 50% (3,4).
n patients with HF complicated by AF, these outcomes are
ven worse (5), with potentially longer-term impact on
uality of life and disability because of the enormous risk for
troke. Further complicating the high mortality risk in this
rowing patient population are the challenges of appropriate
reatment, including stroke prophylaxis. Despite the ab-
ence of contraindications to warfarin, many eligible pa-
ients do not receive oral anticoagulation as recommended
n the American College of Cardiology/American Heart
ssociation (ACC/AHA) HF management guidelines (6).
See page 1290
n 2005, the ACC/AHA Clinical Performance Measures
or Adults with Heart Failure included a performance
easure of the use of warfarin at hospital discharge in allatients with HF and AF without contraindications (7).
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September 29, 2009:1280–9 Quality of Care in AFDespite the very high prevalence of AF in patients with
F (8,9), little is known about the quality of care for AF in
ontemporary patients hospitalized with HF. The goal of
his study is to examine characteristics, treatments, and
uality measure performance in patients hospitalized with
F and AF in the Get With The Guidelines (GWTG)-HF
egistry. Furthermore, this analysis attempts to define fac-
ors associated with appropriate warfarin use in this rapidly
nlarging patient population.
ethods
ata collection. Data were collected through the GWTG
rogram, a national, ongoing, prospective, observational data
ollection and quality improvement initiative started in the
ear 2000 under the guidance and sponsorship of the AHA.
he GWTG program and its component data elements
ave been described previously (10,11). Beginning in Janu-
ry 2005, patients hospitalized with new or worsening HF
r those patients in whom significant HF symptoms devel-
ped during hospitalization for another primary diagnosis
i.e., HF was the primary discharge diagnosis) were enrolled
nto the registry, regardless of their left ventricular function.
articipating centers were instructed to submit data on
onsecutive eligible HF patients to the GWTG-HF regis-
ry. Hospital teams used HF case-ascertainment methods
imilar to those of the Joint Commission.
All participating institutions were required to comply
ith local regulatory and privacy guidelines and, if required,
o secure institutional review board approval. Because data
ere used primarily at the local site for quality improve-
ent, sites were granted a waiver of informed consent under
he common rule. Outcome Sciences served as the registry
oordinating center. The Duke Clinical Research Institute
erved as the data coordinating center and analyzed the
ggregate de-identified data for research purposes.
Trained personnel abstracted the data using standardized
efinitions for all data elements, including AF, HF, isch-
mic versus nonischemic etiology, and comorbidities. Pa-
ients were assigned to race/ethnicity categories using op-
ions defined by the electronic case report form. Other
ariables included demographic and clinical characteristics,
edical history, admission laboratory data, previous treat-
ents, inpatient procedures (including cardioversion), con-
raindications for evidence-based therapies, and in-hospital
utcomes.
Data collection on rhythm status included prior history of
hronic or recurrent AF, prior history of atrial flutter, and
he presence of AF on admission. With respect to warfarin
se at discharge, appropriate eligibility was captured. The
ollowing contraindications to warfarin use were recorded:
llergy to warfarin, pregnancy, excess bleeding risk, excess
all risk, other medical contraindications, or patient reasons.
sing a web-based system, data quality was monitored to
nsure the completeness and accuracy of the submitted data.
ata edit checks were performed to ensure the validity of phe collected data. Only sites and
ariables with a high degree of
ompleteness were used in the
nalysis.
tudy population. From January
, 2005, through March 25, 2008,
04,268 admissions with HF were
ischarged from 340 hospitals par-
icipating in GWTG-HF. We
xcluded 31,548 patients from
5 sites that participated in
WTG-HF in a limited way
nd reported medical histories
ith 75% completeness. There
ere 72,720 admissions with HF
hat were discharged from 255 hospitals participating in the
omplete GWTG-HF registry. We excluded 186 patients
ecause of conflicting data fields. The final overall study
opulation included 72,534 HF admissions.
utcome measure. The primary outcome (and perfor-
ance measure) was warfarin use at discharge among
ligible patients with a history of AF or AF on admission
ithout documented contraindications, intolerance, or
ther documented reasons for not prescribing warfarin.
Secondary analyses were planned to ascertain whether
arfarin use at discharge varied according to risk stratifica-
ion by the CHADS2 (congestive heart failure, hyperten-
ion, age 75, diabetes, and prior stroke or transient
schemic attack) score, across hospital sites, and finally,
hether warfarin use improved with time.
tatistical analysis. Using chi-square tests for categorical
ariables and the Kruskal-Wallis test for continuous vari-
bles, baseline characteristics were compared between:
) patients with no history of AF; 2) patients with a history
f AF only; and 3) patients with AF at the time of their
dmission. Medians and interquartile ranges (IQRs) were
etermined for continuous variables and percentages for
ategorical variables. Univariate analyses and multivariable
ogistic regression were used to identify important factors
ssociated with warfarin use at discharge among eligible
atients. In univariate analyses, the Wilcoxon rank sum test
as used for continuous variables, and the Pearson chi-
quare test was used for categorical variables. Generalized
stimating equations were used to adjust for clustering
ithin hospitals (12). Candidate variable selection was
ased on prior GWTG analyses, essential baseline demo-
raphics, and clinical experience. The initial model in-
luded variables for age, sex, race, geographic region,
ospital type, systolic blood pressure, heart rate (HR),
ody mass index, left ventricular ejection fraction (LVEF),
nemia, AF, cerebrovascular disease (stroke or transient
schemic attack), chronic obstructive pulmonary disease,
oronary artery disease, depression, diabetes mellitus, hy-
erlipidemia, hypertension, nonischemic cardiomyopathy,
Abbreviations
and Acronyms
ACC/AHA  American
College of Cardiology/
American Heart Association
AF  atrial fibrillation
GWTG  Get With
The Guidelines
HF  heart failure
HR  heart rate
IQR  interquartile range
LVEF  left ventricular
ejection fractioneripheral vascular disease, renal insufficiency, smoking,
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Quality of Care in AF September 29, 2009:1280–9hronic dialysis, prior history of revascularization (coronary
ypass grafting or percutaneous intervention), and anti-
latelet therapy at discharge (aspirin, clopidogrel, or both).
nteraction terms were included for race*geographic region.
ignificant variables were selected using backward elimina-
ion at the p 0.1 level. Factors that were insignificant were
emoved from the logistic regression model. All tests were
-tailed, and statistical significance was declared when p 
.05. All analyses were performed using SAS software
ersion 9.0 (SAS Institute, Inc., Cary, North Carolina).
Patient Admission CharacteristicsTable 1 Patient Admission Characteristics
Characteristic
AF on A
(n  1
Age, yrs 79 (70
Women 4
Race
Black 1
Hispanic
White 8
Insurance status
Medicare 6
Medicaid
Other 1
No insurance
Systolic blood pressure, mm Hg 132 (11
Heart rate, beats/min 83 (70
Body mass index, kg/m2 28 (24
LVEF, % 40 (26
LVEF 40% 4
History of
Anemia 1
Atrial flutter
Stroke or transient ischemic attack 1
Chronic dialysis
Depression 1
Diabetes mellitus 3
Hyperlipidemia 3
Hypertension 7
Implantable cardioverter-defibrillator 1
Ischemic heart disease 4
Peripheral vascular disease 1
Prior myocardial infarction 1
Pulmonary disease 3
Renal insufficiency (creatinine 2.0 mg/dl) 1
Revascularization (CABG or PCI) 2
Smoking 1
Laboratory data
BNP, pg/ml 755 (40
N-terminal pro-BNP, pg/ml 6,068 (2,7
Blood urea nitrogen, mg/dl 26 (18
Creatinine, mg/dl 1.3 (1.0
Hemoglobin, g/dl 12 (10
Sodium, mEq/l 138 (13
Hospital bed size 349 (21
Transferred in from another institution
Values are presented as % or median (interquartile range). *Among p
AF  atrial fibrillation; BNP  brain natriuretic peptide; CABG  coronary a
percutaneous coronary intervention.esults
aseline characteristics. Among 72,534 admissions for
F, 47,715 (65.8%) did not have a history of AF and 9,918
13.7%) had a prior history of AF but were in a regular
hythm at admission; 1 in 5 HF admissions presented in AF
n  14,901 of 72,534 or 20.5%). Of those patients who
resented in AF, 11,551 (77.5%) also had a history of prior
F. As shown in Table 1, compared with patients with no
istory of AF, patients who presented in AF more often
ion
)*
History of AF Only
(n  9,918)
No AF
(n  47,715)
79 (70–85) 72 (59–82)
49.2 49.5
12.1 24.3
2.7 5.9
80.8 63.6
70.7 55.1
7.7 11.9
14.1 19.3
1.5 5.7
) 132 (115–151) 140 (120–162)
80 (70–97) 83 (70–97)
27 (24–33) 28 (24–34)
40 (25–55) 38 (25–55)
41.6 47.8
17.5 15.3
8.1 0
16.2 12.2
2.5 5.0
9.8 9.4
38.7 43.9
37.6 36.5
68.5 70.8
11.3 9.0
50.1 46.3
13.1 10.8
7.0 13.9
29.8 26.8
21.0 19.0
29.5 26.6
10.2 19.6
8) 760 (411–1,429) 928 (441–1,910)
,309) 5,254 (2,424–11,183) 5,574 (2,144–13,768)
26 (19–40) 25 (17–38)
1.4 (1.0–1.8) 1.3 (1.0–1.9)
4) 12 (10.7–13.4) 12 (10.5–13.5)
) 138 (135–141) 138 (136–141)
) 349 (194–527) 334 (216–505)
3.2 4.4
with AF on admission, 11,551 (77.5%) had a history of prior AF.dmiss
4,901
–85)
8.5
0.4
3.2
1.6
7.2
7.5
4.4
1.8
5–151
–100)
–33)
–55)
0.0
8.1
4.2
5.5
2.2
0.1
6.2
7.8
0.2
0.8
7.5
1.4
8.6
0.0
8.1
7.6
0.9
9–1,49
58–12
–39)
–1.8)
.6–13.
5–141
6–553
5.2
atients
rtery bypass grafting; LVEF  left ventricular ejection fraction; PCI 
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September 29, 2009:1280–9 Quality of Care in AFere white, were anemic, and had a lower prevalence of
iabetes and renal insufficiency. Patients admitted with AF
ere more likely to have HF with preserved systolic func-
ion because they had a higher median LVEF (40% vs. 35%)
nd a lower incidence of significant left ventricular dysfunc-
ion (40% vs. 47.8% with an LVEF 40%). Patients
dmitted in AF were more likely to have a history of stroke
r transient ischemic attack (15.5% vs. 12.2%). Patients
dmitted with AF also were more likely to be transferred in
rom another institution. Among the patients with AF on
dmission, 23.9% (n  3,172 of 13,269) had an HR 100
eats/min and 8.8% (n  1,163 of 13,269) had an HR
120 beats/min, consistent with a rapid ventricular re-
ponse. The median (IQR) LVEF of patients with an
dmission HR 120 beats/min was 40% (interquartile
ange 25% to 55%).
Among eligible patients with a prior history of AF, 51.3%
ere treated with warfarin before admission, and this
ecreased over time (p value for trend 0.0001). Among
he 24,819 HF admissions with AF (prior history or AF on
dmission), 2,290 (9.2%) had documented contraindica-
ions to warfarin therapy, including an allergy to warfarin
n  37 of 2,290; 1.6%), pregnancy (n  0 of 2,290), excess
leeding risk (n  713 of 2,290; 31.1%), excess fall risk
n  428 of 2,290; 18.7%), or other documented contrain-
ications (n  1,208 of 2,290; 52.8%).
arfarin use at discharge. Among eligible patients, the
edian prevalence of warfarin therapy at discharge was
4.9% (IQR 55.5% to 73.4%). Because the primary aim of
ur analysis was to describe the use of warfarin at discharge,
e examined factors associated with warfarin use in the
5,748 patients with AF (prior history or AF on admission)
ho had no contraindications to warfarin. In univariate
nalysis, we found that older patients, women, black pa-
ients, Medicaid recipients, and those with a history of
oronary artery disease, anemia, and renal insufficiency were
ess likely to be discharged on warfarin (Table 2). Addition-
lly, HF admissions at smaller hospitals, nonacademic
ospitals, and hospitals without house staff or interventional
apabilities were less likely to discharge patients on warfarin.
As shown in Table 3, multivariable logistic regression
dentified discharge on antiplatelet therapy, anemia, renal
nsufficiency, and nonwhite race as factors independently
ssociated with higher odds of no warfarin use at discharge
n patients with AF (p  0.001). With respect to sex, there
as less warfarin use in women (p  0.001). Finally,
atients treated in the southern U.S. were less likely to
eceive warfarin at discharge (p  0.047). The race*region
nteraction was not significant and was not included in the
nal model (Table 3). Finally, we conducted a sensitivity
nalysis restricted to only those patients with AF on
dmission. The results of this multivariable model for
actors associated with nonwarfarin use at discharge were
imilar (Online Appendix 1). Eligible patients who were
dmitted with AF were more likely to receive anticoagula-
ion at discharge than those patients with a history AF who Cere in a regular rhythm at admission (68.5% vs. 60.7%,
 0.0001).
isk stratification and warfarin use. The ACC/AHA/
hysician Consortium AF and Atrial Flutter Performance
easures (13) call for assessment and documentation of
hromboembolic risk factors. To examine the relationship
etween risk factors for stroke and use of anticoagulation,
e analyzed warfarin use at discharge in eligible patients
ccording to the CHADS2 risk stratification scheme (14).
s illustrated in Figure 1, there was significant risk–
reatment mismatch. Warfarin use declined in patients with
ncreasing risk for stroke, as indexed by higher CHADS2
cores (p  0.0001). Among patients with HF as their only
isk factor, 71% were prescribed warfarin, compared with
0% among patients with a CHADS2 score of 6.
ariation in warfarin prescribing. To assess how prescrip-
ion of warfarin at discharge varied at different hospitals, we
nvestigated the variance among warfarin use at discharge
cross sites. The use of warfarin at discharge at each site
anged from 0 to 95.5% and is shown in Figure 2. There was
ess interhospital variation in documented contraindica-
ions/other reasons for not prescribing warfarin in AF
atients with HF (median 6.5%, IQR 0% to 13.5%). We also
xamined the trend in warfarin use over the 3.5 years of the
tudy. In both quarterly and yearly assessments, there was no
vidence of increasing use of warfarin at discharge with time
Fig. 3). In 2005, 62.2% of eligible patients were discharged on
arfarin, compared with 66.8% in 2006, 65.5% in 2007, and
3.5% in the first quarter of 2008 (p  0.1457).
ombination antithrombotic pharmacotherapy. Because
ome patients may have received stroke prophylaxis other
han warfarin, or combination antithrombotic therapy, we
lso examined the use of other antithrombotic medications
t discharge (Fig. 4). Among the 15,748 patients with a
istory of AF or AF on admission, the most common
ischarge antithrombotic strategy was warfarin mono-
herapy (n  5,913, 37.6%). Eighty-nine percent of the
ohort was taking at least some form of antithrombotic
herapy (either warfarin or an antiplatelet agent). The use of
ombination antiplatelet therapy with warfarin, so-called
riple therapy, was only documented in 3.4% (n  531).
mong patients on triple therapy, only 10.9% had a
ercutaneous coronary intervention (n  58). Finally, 1 in
0 patients with a diagnosis of AF was not taking any
edication for stroke prophylaxis.
iscussion
sing GWTG-HF, a nationwide clinical practice registry,
e examined the quality of care for AF in over 70,000 HF
dmissions at more than 250 clinical sites. There were 4
ain findings in our analysis. First, stroke prophylaxis is
ignificantly underused in eligible patients with AF and HF.
econd, there is a significant risk–treatment mismatch
n stroke prevention, such that patients with higher
HADS2 scores were less likely to receive anticoagulation.
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Quality of Care in AF September 29, 2009:1280–9Univariate Associations With Discharge Warfarin Use Among Eligible Patients With AFTable 2 Univariate Associations With Discharge Warfarin Use Among Eligible Patients With AF
Variable
Warfarin
(n  10,273)
No Warfarin
(n  5,475) p Value
Age, yrs 76 (67–83) 79 (70–85) 0.0001
Female 43.3 47.5 0.0001
Race 0.0001
Black 11.5 14.6
Hispanic 3.3 3.5
White 80.8 76.5
Insurance status 0.0001
Medicare 65.9 65.7
Medicaid 6.7 8.6
Other 17.0 15.7
No insurance 2.1 1.9
Systolic blood pressure, mm Hg 132 (116–151) 136 (117–156) 0.0001
Heart rate, mm Hg 82 (70–99) 80 (70–96) 0.0001
Body mass index, kg/m2 29 (24–34) 27 (23–33) 0.0001
LVEF, % 40 (25–55) 40 (25–55) 0.0009
LVEF 40% 45.4 41.5 0.0002
History of
Anemia 13.2 18.6 0.0001
Atrial flutter 6.0 6.5 0.2236
Chronic or recurrent atrial fibrillation 84.5 79.8 0.0001
Chronic dialysis 1.6 3.3 0.0001
Depression 7.9 8.7 0.0891
Diabetes mellitus 37.0 37.5 0.5472
Hyperlipidemia 40.3 39.9 0.6750
Hypertension 69.6 70.0 0.6086
ICD 14.0 10.7 0.0001
Ischemic heart disease 47.9 51.5 0.0001
Peripheral vascular disease 10.9 12.3 0.0074
Prior myocardial infarction 14.1 15.0 0.1352
Pulmonary disease 28.1 29.6 0.0440
Renal insufficiency (creatinine 2.0 mg/dl) 16.0 19.7 0.0001
Revascularization (CABG or PCI) 29.9 32.5 0.4591
Smoking 11.9 13.2 0.0161
Stroke or transient ischemic attack 14.1 13.8 0.7195
Laboratory data
BNP, pg/ml 660 (362–1,256) 774 (418–1,462) 0.0001
N-terminal pro-BNP, pg/ml 4,601 (2,238–9,308) 6,199 (2,992–13,987) 0.0001
Blood urea nitrogen, mg/dl 24 (18–35) 25 (18–37) 0.0252
Creatinine, mg/dl 1.3 (1.0–1.7) 1.3 (1.0–1.8) 0.0001
Hemoglobin, g/dl 12.4 (11–13.7) 12 (10.6–13.4) 0.0001
Sodium, mEq/l 138 (136–141) 138 (135–141) 0.6683
In-hospital procedures
ICD implantation 5.2 4.2 0.0173
Cardioversion 3.6 1.4 0.0001
PCI 0.4 0.6 0.0379
Hospital characteristics
Hospital bed size 355 (233–571) 338 (200–553) 0.0001
Academic hospital 60.3 55.5 0.0001
No house staff 37.9 41.4 0.0004
No interventional capabilities 29.6 32.1 0.0013
Region 0.0001
West 10.0 10.1
South 31.3 36.5
Midwest 30.9 27.8
Northeast 28.1 25.7Values are presented as % or median (interquartile range).
ICD  implantable cardioverter-defibrillator; other abbreviations as in Table 1.
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September 29, 2009:1280–9 Quality of Care in AForeover, despite national guideline recommendations and
n ACC/AHA performance measure for anticoagulation at
he time of hospital discharge, warfarin use has not im-
roved with time. Finally, we found that there are several
mportant factors associated with warfarin underuse, includ-
Multivariable Factors Associated With NonwarfaTable 3 Multivariable Factors Associated W
Patient Characteristics
Systolic blood pressure (per 10-mm Hg increase)
Antiplatelet therapy at discharge
Both (vs. none)
Clopidogrel only (vs. none)
Aspirin only (vs. none)
Age (per 10-yr increase)
Anemia
Race (white vs. nonwhite)
Body mass index (per 5-U increase)
Insurance status
Medicaid (vs. no insurance)
Medicare (vs. no insurance)
Other (vs. no insurance)
Diastolic blood pressure (per 10-mm Hg increase)
Renal insufficiency
Number of beds (per 100-bed increase)
Region
Midwest (vs. Northeast)
South (vs. Northeast)
West (vs. Northeast)
Female vs. male
COPD or asthma
Prior stroke or transient ischemic attack
Hyperlipidemia
Hypertension
Heart rate (per 10 beats/min increase)
CI  confidence interval; COPD  chronic obstructive pulmonary dise
Figure 1 Warfarin Use at Discharge Among Eligible Heart Failu
Among eligible heart failure patients with atrial fibrillation (n  15,748), warfarin u
(congestive heart failure, hypertension, age 75, diabetes, and prior stroke or trang age, race, clopidogrel use, and treatment at smaller
ospitals.
Given the increasing prevalence of both HF and AF,
mproving the quality of care for AF is paramount in this
atient population. The ACC/AHA guidelines for the
se at Dischargeonwarfarin Use at Discharge
uare OR 95% CI p Value
4 1.07 1.06–1.09 0.001
1 6.21 5.15–7.49 0.001
3.46 2.83–4.23
2.55 2.25–2.89
6 1.21 1.15–1.27 0.001
0 1.46 1.31–1.64 0.001
8 0.68 0.60–0.78 0.001
7 0.92 0.90–0.95 0.001
6 0.94 0.70–1.27 0.001
0.66 0.49–0.89
0.79 0.59–1.05
6 0.94 0.92–0.97 0.001
0 1.24 1.13–1.36 0.001
0 0.91 0.87–0.95 0.001
6 1.07 0.87–1.32 0.007
1.37 1.14–1.64
1.32 1.02–1.72
0 1.14 1.05–1.23 0.001
10 1.12 1.03–1.21 0.005
47 0.85 0.76–0.95 0.006
43 0.92 0.86–0.98 0.017
21 0.92 0.83–1.01 0.073
14 0.98 0.96–1.00 0.120
 odds ratio.
tients According to the CHADS2 Score
clined with increasing risk for stroke, as indexed by higher CHADS2
ischemic attack) scores (p for trend 0.0001).rin Uith N
Chi-Sq
77.3
70.4
52.1
44.1
31.7
26.9
24.3
21.0
20.0
16.6
12.2
10.8
7.9
7.6
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Quality of Care in AF September 29, 2009:1280–9anagement of chronic HF have advocated the use of
arfarin for stroke prophylaxis in patients with paroxysmal
r persistent AF since 2005 (Class I recommendation; Level
f Evidence: A) (6,7). The 2005 ACC/AHA HF perfor-
ance measures include a hospital performance measure for
he use of warfarin at hospital discharge in all eligible
atients without contraindications. Although warfarin un-
eruse has been well documented in other AF populations
15–17), the significant underuse of warfarin (a proven
ifesaving intervention) in this cohort of hospitalized HF
atients is cause for concern. Despite unequivocal guideline
ecommendations, 1 in 3 eligible patients was not dis-
harged on warfarin. Furthermore, there was no evidence of
ongitudinal incorporation of guideline recommendations
ecause rates of warfarin use did not improve over time.
The warfarin underuse in this real-world population has
ignificant implications. The decision to anticoagulate pa-
ients requires a careful balance of the risks and benefits.
Figure 2 Warfarin Use at Discharge at Each Site Among Eligibl
At the site level (n  146), warfarin use had high variation, ranging from 0% to 95
Figure 3 Warfarin Use at Discharge Across Time
Among eligible heart failure patients with atrial fibrillation, there was no evi-
dence of increasing use of warfarin at discharge with time, in either quarterly
(p  0.126) or yearly (p  0.146) assessments.onsidering the mean CHADS2 score of 3 in our hospi-
alized cohort, the risk of stroke or transient ischemic attack
ould be estimated at 5.9% per year (18). Therefore, the
ailure to prescribe warfarin (which is associated with a
wo-thirds reduction in stroke risk, or one-third reduction
hen compared with aspirin) (19) in the 5,475 HF admis-
ions could have led to between 110 and 216 preventable
hromboembolic events. If these findings are generalized to
he entire U.S. populations hospitalized with HF and AF,
here may be as many as 7,000 preventable thromboembolic
vents occurring each year.
rt Failure Patients
Figure 4 Antithrombotic Therapy at Discharge
Shown here is the prevalence of each antithrombotic regiment prescribed at
discharge among eligible patients with heart failure and atrial fibrillation. Eighty-
nine percent of the cohort was taking at least some form of antithrombotic
therapy (either warfarin or an antiplatelet agent).e Hea
.5%.
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September 29, 2009:1280–9 Quality of Care in AFAn equally important finding in our analysis was the
iscovery of wide interhospital variance in warfarin use at
ischarge. Site-specific warfarin use at discharge varied
idely, ranging between 0% and 96%. Significant inter-
ospital variance has been described previously for other
vidence-based therapies (10,20). In this HF registry,
maller hospital size was associated with decreased warfarin
se. This association may reflect differences in hospital
esources. Smaller hospitals may not have sufficient volume
o afford the use of formal or automated stroke prophylaxis
creening tools. Hopefully, emphasis on performance mea-
ures will help ameliorate this variance.
In addition to interhospital variation, we also identified
ignificant regional variation in the use of warfarin at
ischarge. Warfarin use at discharge was greatest in the
ortheast, whereas treatment in the South was associated
ith lower rates of warfarin use. The relationship between
ecreased warfarin use and treatment in the South persisted
fter adjustment for multiple clinical factors, including race.
his regional variation has important implications, given
he higher prevalence of stroke and higher stroke-related
ortality in the South (21,22).
The CHADS2 index is a validated risk stratification tool
or stroke risk in patients with nonvalvular AF, and its use
s advocated in the ACC/AHA/European Society of Car-
iology 2006 guidelines for the management of patients
ith AF (18). Increasing CHADS2 scores reflect increasing
isk for stroke. In this cohort, higher CHADS2 scores were
aradoxically associated with decreased warfarin use. This
isk–treatment mismatch is surprising given the increased
agnitude of benefit and absolute risk reduction in these
igh-risk patients (23,24). Previously, it has been observed
hat patients at the highest risk are less likely to receive
nvasive or interventional procedures (25,26). Similarly,
lderly patients with AF are also less likely to receive
nticoagulation, presumably because of perceived increased
isks and imbalance in the risk–benefit ratio. Given the
xtremely low rates of intracranial bleeding, the mortality
enefit afforded with warfarin therapy, and the increased
isk of thromboembolism in these patients, warfarin should
e the preferred therapy (27,28). Substitution of aspirin
hould only occur in patients with significant risk of
leeding. The use of some form of antithrombotic therapy
n 89% of patients, paired with warfarin underuse and the
arked risk–treatment mismatch observed in this popula-
ion, suggests that stroke risk is not adequately influencing
nticoagulation decisions in patients with AF and HF.
Concordant with the observed risk–treatment mismatch
etween CHADS2 scores and rates of warfarin use, our
nalysis also showed that nonwhite patients were 30% less
ikely to receive warfarin for stroke prophylaxis. Despite an
ncreased risk for stroke, black patients were less likely to
eceive warfarin. Finally, the decreased warfarin use in
omen is also a cause for concern given the increased risk oftroke in women relative to men. qAmong the warfarin-eligible patients in this cohort,
pproximately 1 in 4 were receiving antiplatelet therapy only
16% aspirin only, 2% clopidogrel only, and 5% aspirin and
lopidogrel). Although one could advocate that these pa-
ients were low risk and could be appropriately treated with
ntiplatelet therapy only, recent and prior trial evidence has
hown that oral anticoagulation is superior to antiplatelet
herapy (19,29). Although some evidence suggests that HF
s not a potent risk factor for stroke (30), several studies have
learly established increased risk in patients with HF
14,31). Consistent with this increased risk, the ACC/AHA
uidelines for the management of patients with HF and the
merican College of Chest Physicians practice guidelines
or antithrombotic therapy in AF recommend warfarin for
ll eligible HF patients with AF (6,32).
Currently, there is a great deal of controversy regarding
he appropriate antithrombotic regimen in patients with AF
nd an indication for extended dual antiplatelet therapy
e.g., placement of a drug-eluting stent). So-called triple
herapy (warfarin with aspirin and a thienopyridine) has
een associated with increased bleeding; however, with-
olding anticoagulation in this patient population is also
ssociated with increased mortality (28,33). The 2006
CC/AHA/Heart Rhythm Society guidelines for the man-
gement of patients with AF advocate treatment with
arfarin and the addition of a thienopyridine for the
aintenance of stent patency (18). This recommendation is
ased on expert opinion (Level of Evidence: C). In our
nalysis, clopidogrel use at discharge was a strong, indepen-
ent predictor of discharge without warfarin. Although
here is no therapeutic consensus, given the available data
nd the magnitude of stroke risk compared with the
elatively rarity of stent thrombosis (34), warfarin should not
e withheld in patients with AF and HF. Additionally, the
ombination of aspirin and clopidogrel has been shown to
e inferior to warfarin for the prevention of stroke in
atients with AF (29). Although further research and
ong-term outcome data are needed, this is an important
pportunity for targeted quality improvement initiatives.
tudy limitations. First, although we controlled for many
linical variables known to be associated with an increased
isk for bleeding and we excluded those patients in whom an
ncreased risk of bleeding was documented, we did not have
ata on prior bleeding events. Second, data were collected
y medical chart review and are dependent on the accuracy
nd completeness of documentation and abstraction. Con-
raindications and intolerance were recorded as noted in the
edical record, but a proportion of untreated patients we
lassified as eligible for treatment may have had contrain-
ications or intolerance that were indeed present but not
ocumented. Fourth, the GWTG database currently does
ot track post-discharge treatment and outcomes. Although
he link between the anticoagulation for AF as a process
uality measure and adverse post-discharge outcomes may
e valid, we were not able to directly explore the conse-
uences of lack of anticoagulation in this patient population.
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Quality of Care in AF September 29, 2009:1280–9inally, the voluntary GWTG program may include
ospitals with a higher likelihood of following evidence-
ased recommendations, therefore biasing our observa-
ions toward conservative estimates. Prior studies of the
PTIMIZE-HF (Organized Program to Initiate Life-
aving Treatment in Hospitalized Patients with Heart
ailure) trial and other HF registries have shown that
atients admitted with HF have similar baseline character-
stics to patients from national datasets, suggesting that data
rom registry hospitals are likely to be representative of
ational trends and practices (18,35). Nonetheless, our
tudy represents the largest description of warfarin use in an
ligible, real-world HF population.
onclusions
ore than one-third of patients hospitalized with HF have
history of AF or present with AF on admission.
uideline-recommended warfarin use in eligible patients
ith HF and AF is less than optimal and varies significantly
ccording to age, race, comorbidities, region, and hospital
ite. There is a significant risk–treatment mismatch, with
F patients with higher CHADS2 scores less likely to
eceive anticoagulation. Anticoagulation in patients with
F and HF represents a significant opportunity for quality
mprovement.
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APPENDIX
or a table on the factors associated with nonwarfarin use at discharge
mong patients with atrial fibrillation on admission, please see the online546S–92S. version of this article.
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